CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
February 05 2009 - 8:30AM
PR Newswire (US)
ATLANTA, Feb. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc.
(NYSE:CRY), a biomaterials, medical device and tissue processing
company, announced today that 2008 fourth quarter and year end
financial results will be released on Thursday, February 19, 2009.
The Company will hold a teleconference call and live webcast at
10:00 a.m. Eastern Time, February 19, 2009, to discuss the results,
followed by a question and answer session hosted by Steven G.
Anderson, president and CEO of CryoLife, Inc. To listen to the live
teleconference, please dial 201-689-8261 a few minutes prior to
10:00 a.m. A replay of the teleconference will be available
February 19 through February 26 and can be accessed by calling
(toll free) 877-660-6853 or 201-612-7415. The account number for
the replay is 244 and the conference number is 312509. The live
webcast and replay can be accessed by going to the Investor
Relations section of the CryoLife web site at
http://www.cryolife.com/ and selecting the heading Webcasts &
Presentations. About CryoLife, Inc. Founded in 1984, CryoLife, Inc.
is a leader in the processing and distribution of implantable
living human tissues for use in cardiac and vascular surgeries
throughout the U.S. and Canada. The Company recently received FDA
clearance for the CryoValve(R) SG pulmonary human heart valve,
processed using CryoLife's proprietary SynerGraft(R) Technology.
The Company's BioGlue(R) Surgical Adhesive is FDA approved as an
adjunct to sutures and staples for use in adult patients in open
surgical repair of large vessels. BioGlue is also CE marked in the
European Community and approved in Canada and Australia for use in
soft tissue repair. CryoLife distributes Hemostase MPH, a
hemostatic agent, in much of the U.S. for use in cardiac and
vascular surgery and in the United Kingdom, Germany, France and
Canada for cardiac, vascular, and general surgery, subject to
certain exclusions. The Company also distributes the
CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which
is CE marked for distribution within the European Community. For
additional information about the company, visit CryoLife's Web
site: http://www.cryolife.com/. D. Ashley Lee Katie Brazel
Executive Vice President, Fleishman Hillard Chief Financial Officer
and Phone: 404-739-0150 Chief Operating Officer Phone: 770-419-3355
DATASOURCE: CryoLife, Inc. CONTACT: D. Ashley Lee, Executive Vice
President, Chief Financial Officer and Chief Operating Officer,
CryoLife, Inc., +1-770-419-3355; Katie Brazel, Fleishman Hillard,
+1-404-739-0150 Web Site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024